WASHINGTON, Sept 26 (Reuters) - The U.S. Securities and

Exchange Commission said on Thursday that it charged Cassava

Sciences ( SAVA ) and two of the company's former executives for

misleading claims about the results of Alzheimer's clinical

trials.

The SEC said the company's founder and former CEO, Remi

Barbier, and its former senior vice president of neuroscience,

Dr. Lindsay Burns, will pay more than $40 million to settle

charges.